HDAC9 and cancer: Given the correlation between tumorigenesis and mutations in the S-phase checkpoints (Bartkova et al. 2005; Gorgoulis et al. 2005), our observation that HDAC depletion leads to a suppression of lethality of yeast checkpoint mutants is in sharp contrast with the desired toxic effect for HDAC inhibitors in cancer.